Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
With 53% institutional ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) is a favorite amongst the big guns | Nasdaq
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
10 Takeover Targets of 2018
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
UBS Has Nine Biotech Buyout and Merger Candidates – 24/7 Wall St.
Opinion: 5 biotech stocks that could be the next big winners - MarketWatch
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Bio: Now Or Never. I Go With Never (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
Puma and CANBridge cancel licensing deal for $20m
Puma Biotechnology
Opinion: 15 biotech stocks to put on your watch list now - MarketWatch
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotech punts near $300 million on Takeda discard
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
